Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

PP405 is in a phase 3 trial for hair loss treatment, with the study expected to run until June 2028. Minoxidil and finasteride remain key treatments, with hopes for PP405 to offer a new mechanism of action.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

The user experienced significant hair improvement using a topical mix of finasteride (0.025%), minoxidil (5%), and pyrilutamide (0.5%) without side effects. They noticed visible results within two months and attributed the success mainly to minoxidil.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

Setipiprant may help with hair maintenance but is not a guaranteed solution for everyone. Other treatments like minoxidil, finasteride, and topical spironolactone are discussed, with varying opinions on their effectiveness.

The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

The user shared their 6-month progress using 0.25 mg finasteride, topical minoxidil, and dermastamping, noting good results but experiencing increased sleepiness. Another user suggested minoxidil might be causing the sleepiness, and the original poster considered adjusting their treatment.

The conversation discusses using minoxidil 5% and finasteride 1.25mg daily for hair loss, with the user experiencing monthly shedding and a slight decrease in sex drive as a side effect. The user also mentions using a shampoo with piroctone olamine for seborrheic dermatitis and considers oral minoxidil to reduce scalp irritation.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

The conversation is about using a topical finasteride solution without minoxidil to avoid side effects, with suggestions to use alternatives like a PG solvent or Stemox. There is also a mention of mixing finasteride with fisetin powder in the solvent.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.

The user switched from finasteride to 2.5 mg dutasteride daily and added 1% pyrilutamide to address persistent scalp itch, but the itch remains. They also use 2% ketoconazole and 2.5% selenium sulfide shampoo for temporary relief.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

The conversation is about the long-term safety trial results for pyrilutamide, which are expected soon. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

Concerns about the legitimacy of pyrilutamide solutions from Farmacia Tristaina due to low prices and lack of testing. Users suggest using Jano testing for product verification.

Actifolic's RU58841 and Pyri products are perceived as ineffective, with users reporting no side effects or improvements, suggesting possible quality issues. Users recommend alternative sources and emphasize the importance of timing when using RU58841 with Minoxidil.

PP405 was ineffective for hair growth as some follicles were already active before treatment, raising doubts about its efficacy. Users discussed other hair loss treatments like Minoxidil, finasteride, and RU58841, expressing skepticism and hope for future solutions.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.

PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.